Sunday, 20 September 2026

Ceperognastat

 

Ceperognastat

CAS 2241514-56-5

MF C16H22FN5O3S MW383.4 g/mol

Acetamide, N-(4-fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-piperidinyl)methyl)-2-thiazolyl)-

N-[4-fluoro-5-({(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl}methyl)-1,3-thiazol-2-yl]acetamide
O-GlcNAcase (OGA) enzyme inhibitor, LY3372689, LY3372689, U0SGP6ZX2V

Ceperognastat (LY3372689) is a drug candidate molecule under investigation to treat Alzheimer's disease. It targets the enzyme O-GlcNAcase.[2][3] Its result is to reduce formation of tau protein tangles.

A molecule containing radioactive fluorine was used with a PET scan to show that ceperognastat binds in the human brain.[4]

Ceperognastat was discovered via a high-throughput screening campaign followed by further optimization.[5]

Eli Lilly and Company is recruiting subjects for a clinical trial.[6] Some hospitals in Australia: St Vincent's Hospital, Sydney Hornsby Ku-Ring-Gai Hospital, The Prince Charles Hospital, The Queen Elizabeth Hospital, Adelaide, Box Hill Hospital, and Delmont Private Hospital are involved.[7] Results of the trial were expected by June 2024.[8] Primary completion of the study occurred on 9th July 2024, with full completion expected in August 2024. In an investor call, it was disclosed that ceperognastat missed the primary endpoint of improvement on the Integrated Alzheimer's Disease Rating Scale. The detailed results of this study are expected to be disclosed at a conference in late 2024.[9]

Chemical

The molecule contains three rings: thiazole, piperidine and oxadiazole. Other functional groups included are an ether, acetamide, and a fluoride.[10]

  • A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseCTID: NCT05063539Phase: Phase 2Status: CompletedDate: 2025-07-28
  • A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy ParticipantsCTID: NCT04392271Phase: Phase 1Status: CompletedDate: 2020-11-04
  • A Safety Study of LY3372689 in Healthy ParticipantsCTID: NCT04106206Phase: Phase 1Status: CompletedDate: 2020-04-24
  • A Study of the Effects of LY3372689 on the Brain in Healthy ParticipantsCTID: NCT03944031Phase: Phase 1Status: CompletedDate: 2020-04-22
  • A Safety Study of LY3372689 Given By Mouth to Healthy ParticipantsCTID: NCT03819270Phase: Phase 1Status: CompletedDate: 2019-07-05

REF

SYN

https://patentscope.wipo.int/search/en/detail.jsf?docId=US224106869&_cid=P22-MO2ADF-16767-1

EXAMPLE 1

Synthesis of N-[4-fluoro-5-[[(2S,5S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide

 N-(4-Fluoro-5-formyl-thiazol-2-yl)acetamide (28.3 g, 150 mmol) is added to 5-methyl-3-[[(2S,4S)-2-methyl-4-piperidyl]oxymethyl]-1,2,4-oxadiazole hydrochloride (48.7 g, 185 mmol, 94% purity) in ethyl acetate (707 mL) at room temperature. The reaction mixture is stirred at room temperature and N,N-diisopropylethylamine (34.1 mL, 195 mmol) is added dropwise over 1 minute, then sodium triacetoxyborohydride (98.5 g, 451 mmol) is added in one portion. The reaction mixture is stirred in a 31° C. heating block overnight with an internal temperature of 30° C., then is cooled in an ice-water bath to an internal temperature of 5° C. To the mixture is added 2M aqueous hydrochloric acid solution (226 mL) over 15 minutes, maintaining an internal temperature below 10° C. To the mixture is added water (250 mL) and the mixture is stirred at room temperature for 5 minutes. The layers are separated and the organic layer is extracted with a mixture of 2M aqueous hydrochloric acid solution (28 mL) in water (50 mL). The first aqueous layer is stirred in an ice-water bath and 50% aqueous sodium hydroxide solution (25.7 mL) is added dropwise over 10 minutes, maintaining an internal temperature below 10° C. The mixture is diluted with saturated aqueous sodium bicarbonate solution (100 mL), then is stirred at room temperature for 10 minutes and then is extracted with ethyl acetate (3×400 mL). The combined organics are dried over sodium sulfate, filtered and concentrated to give a residue. The second aqueous layer from the extraction with aqueous hydrochloric acid is diluted with 2-methyltetrahydrofuran (200 mL) and the mixture is passed through a short pad of diatomaceous earth. The filtrate is transferred to a separating funnel and the layers are separated. The aqueous layer is stirred in an ice-water bath and 50% aqueous sodium hydroxide solution (3.15 mL) is added dropwise over 5 minutes, maintaining an internal temperature below 10° C. The mixture is diluted with saturated aqueous sodium bicarbonate solution (10 mL), then is stirred at room temperature for 5 minutes and then is extracted with ethyl acetate (3×40 mL) and 10% isopropanol in ethyl acetate (100 mL). The combined organics are dried over sodium sulfate, filtered and concentrated to give a residue, which is combined with the residue from the first part of the workup. The combined residue is passed through a pad of silica gel (350 g) eluting with ethyl acetate (3.5 L) and the filtrate is concentrated to give a residue (45.8 g).
      The residue (47.5 g of combined lots, 123.9 mmol) is purified by flash chromatography, eluting with 50-100% ethyl acetate in heptane. The product-containing fractions are concentrated to residue, which is suspended in a 1:1 mixture of methyl-tert-butyl ether and heptane (448 mL). The mixture is stirred in a 46° C. heating block for 30 minutes at an internal temperature of 45° C., then is cooled to room temperature over 2 hours with stirring. The mixture is filtered, washing the solid with a 1:1 mixture of methyl-tert-butyl ether and heptane (30 mL). The filtered solid is dried under vacuum at 40° C. overnight to give the title compound (28.5 g). MS m/z 384.0 (M+H); [α] D 20=+33.4° (C=0.26, methanol).

PAT

str1

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

References

  1.  "Data Sheet LY3372689" (PDF). 26 December 2024. Retrieved 4 February 2025.
  2.  "LY3372689". www.alzforum.org.
  3.  Cheng, Steven S.; Mody, Alison C.; Woo, Christina M. (2024-11-07). "Opportunities for Therapeutic Modulation of O-GlcNAc". Chemical Reviews. 124 (22): 12918–13019. doi:10.1021/acs.chemrev.4c00417. ISSN 0009-2665. PMID 39509538.
  4.  Shcherbinin, Sergey; Kielbasa, William; Dubois, Susan; Lowe, Stephen L; Phipps, Krista M; Tseng, James; Kevin, Donnelly B; Natanegara, Fanni; Warner, Susan; Dreyfus, Nicolas; Lindsay-Scott, Peter; Hawk, Mai Khanh; McDonald, Nicholas; Zhang, Xiaoyu; Gilmore, Julie A; Biglan, Kevin; Mergott, Dustin J; Russell, David; Gunn, Roger N; Constantinescu, Cristian; Nuthall, Hugh Norman; Collins, Emily C (December 2020). "Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme: Translation from rat to human: Neuroimaging / evaluating treatments". Alzheimer's & Dementia. 16 (S4). doi:10.1002/alz.040558. S2CID 227501893.
  5.  Kielbasa, William; Goldsmith, Paul; Donnelly, Kevin B.; Nuthall, Hugh N.; Shcherbinin, Sergey; Fleisher, Adam S.; Hendle, Jörg; DuBois, Susan L.; Lowe, Stephen L.; Zhang, Feiyu Fred; Woerly, Eric M.; Dreyfus, Nicolas J.-F.; Evans, David; Gilmore, Jeremy; Mancini, Michele (October 2024). "Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease". Alzheimer's & Dementia: Translational Research & Clinical Interventions. 10 (4) e70020. doi:10.1002/trc2.70020. ISSN 2352-8737. PMC 11694536. PMID 39748851.
  6.  "Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease". clinicaltrials.gov. 22 March 2022. Retrieved 31 March 2022.
  7.  "A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease". Retrieved 31 March 2022.
  8.  Krietsch Boerner, Leigh (25 March 2022). "Hybrid meeting divulges structures of drug candidates". Chemical & Engineering News. ISSN 0009-2347.
  9.  edge.media-server.com https://edge.media-server.com/mmc/p/3kqnwjy6/. Retrieved 2024-10-06. {{cite web}}: Missing or empty |title= (help)
  10.  Dreyfus, Nicolas Jacques Francois; Lindsay-Scott, Peter James (2 August 2018). "N-[4-Fluoro-5-[[(2S,4S)-2-Methyl-4-[(5-Methyl-1,2,4-Oxadiazol-3-Yl)methoxy]-1-Piperidyl]methyl]thiazol-2-Yl]acetamide as Oga Inhibitor". Retrieved 31 March 2022.
Names
IUPAC nameN-[4-fluoro-5-[[2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide
Identifiers
CAS Number2241514-56-5 [1]
3D model (JSmol)Interactive image
ChemSpider129432852
PubChem CID135271363
InChI
SMILES
Properties
Chemical formulaC16H22FN5O3S
Molar mass383.44 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).Infobox references

/////////ceperognastat, O-GlcNAcase (OGA) enzyme inhibitor, LY3372689, LY3372689, U0SGP6ZX2V

#ceperognastat, #O-GlcNAcase (OGA) enzyme inhibitor, #LY3372689, #LY3372689, #U0SGP6ZX2V

Posted by at No comments:

Cirtociclib

 

Cirtociclib

CAS 2888704-84-3

MF C15H17F2N7O2 MW365.34 g/mol

N-[3-(difluoromethoxy)-1H-pyrazol-5-yl]-1-(oxan-4-ylmethyl)pyrazolo[3,4-b]pyrazin-6-amine

N-[5-(difluoromethoxy)-1H-pyrazol-3-yl]-1-[(oxan-4-yl)methyl]-1H-pyrazolo[3,4-b]pyrazin-6-amine
cyclin-dependent kinase inhibitor, antineoplastic, BLU-222, BLU 222, BLU 170298, U93X72ED47, CDK2 Inhibitor BLU-222

Cirtociclib (also known as BLU-222) is an investigational drug that acts as a highly selective inhibitor of cyclin-dependent kinase 2 (CDK2). It is being developed by Blueprint Therapeutics for the treatment of advanced solid tumours, particularly those with genetic drivers like CCNE1 amplification, which are common in certain ovarian and breast cancers

Certociclib is a small molecule drug. Certociclib is under investigation in clinical trial NCT05252416 ((VELA) Study of BLU-222 in Advanced Solid Tumors). Certociclib has a monoisotopic molecular weight of 365.14 Da.

Certociclib is an orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon administration, certociclib selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDK2, a serine/threonine kinase that plays an important role in the regulation of cell cycle progression and cellular proliferation, is overexpressed in certain tumor cells.

How It Works

  • Targeting CDK2: It binds to CDK2, a protein that regulates the cell cycle.
  • Cell Cycle Arrest: By inhibiting CDK2, the drug causes G1 arrest, preventing cancer cells from replicating.
  • Selectivity: It is designed to be "best-in-class" for its high selectivity for CDK2 over other kinases like CDK1, CDK4, or CDK6. 

Therapeutic Potential

  • Ovarian Cancer: Specifically targets high-grade serous ovarian cancer where CCNE1 is amplified.
  • Breast Cancer: Shows promise in treating hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer, especially when the cancer has become resistant to existing CDK4/6 inhibitors.
  • Combination Therapy: Researchers are testing it alongside other drugs, such as palbociclib, ribociclib, or chemotherapy agents like carboplatin, to enhance efficacy. 

Current Status

  • Clinical Trials: It is currently being evaluated in a Phase 1/2 clinical trial known as the VELA study (NCT05252416) for patients with advanced solid tumours.
  • Research Status: It is not yet approved for general medical use and is primarily available for research and clinical trial participants. 

(VELA) Study of BLU-222 in Advanced Solid Tumors

CTID: NCT05252416

Phase: Phase 1

Status: Terminated

Date: 2025-11-28

🌟 Key Point: Cirtociclib represents a new generation of precision medicine aimed at overcoming resistance to standard cancer therapies by specifically targeting the CDK2 pathway

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2026050766&_cid=P22-MO3PRU-93555-1

The structure of one CDK2 inhibitor, referred to herein as “a compound of formula (I)” or N-(5-(difluoromethoxy)-lH-pyrazol-3-yl)-l-((tetrahydro-2H-pyran-4-yl)methyl)-lH-pyrazolo[3,4-b]pyrazin-6-amine is shown below:

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=US398479580&_cid=P22-MO3PW2-97204-1

Example 2

N-(5-(difluoromethoxy)-1H-pyrazol-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrazolo[3,4-b]pyrazin-6-amine

  A mixture of 6-chloro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrazolo[3,4-b]pyrazine (Preparation 87, 780 mg, 3.09 mmol), 5-(difluoromethoxy)-1H-pyrazol-3-amine (554 mg, 3.72 mmol), tBuXphos Pd G3 (150 mg, 0.19 mmol) and KOAc (892 mg, 9.08 mmol) in dioxane (15 mL) was stirred at 90° C. for 6 h under N 2. The reaction mixture was evaporated to dryness in vacuo and the residue was purified by prep-HPLC-4 to afford the title compound as a white solid (361.4 mg, 32%). LCMS m/z=366 [M+H] +; 1H NMR (400 MHz, DMSO-d 6) δ: 12.21 (s, 1H), 10.82 (s, 1H), 8.19 (s, 1H), 8.17 (s, 1H), 7.32 (t, 1H), 5.98 (d, 1H), 4.40 (d, 2H), 3.87-3.75 (m, 2H), 3.29-3.16 (m, 2H), 2.24-2.11 (m, 1H), 1.46-1.29 (m, 4H).

PAT

str1

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

/////////cirtociclib, cyclin-dependent kinase inhibitor, antineoplastic, BLU-222, BLU 222, BLU 170298, U93X72ED47, CDK2 Inhibitor BLU-222

#cirtociclib, #cyclin-dependent kinase inhibitor, #antineoplastic, #BLU-222, #BLU 222, #BLU 170298, #U93X72ED47, #CDK2 Inhibitor BLU-222

Posted by at No comments:

Claturafenib

 

Claturafenib

CAS 2754408-94-9

MF C18H15Cl2F2N5O3S MW490.3 g/mol

N-[2-chloro-3-[(5-chloro-3-methyl-4-oxoquinazolin-6-yl)amino]-4-fluorophenyl]-3-fluoroazetidine-1-sulfonamide

N-{2-chloro-3-[(5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino]-4-fluorophenyl}-3-fluoroazetidine-1-sulfonamide
B-Raf (BRAF) inhibitor, antineoplastic, PF-07799933, PF 07799933, ARRY440, ARRY 440, PC35M52J8T

Claturafenib (development code PF-07799933) is an investigational cancer drug currently being developed by Pfizer. It is a selective, orally active pan-mutant BRAF inhibitor designed to treat advanced solid tumours with specific genetic alterations

Mechanism of Action

Claturafenib belongs to a class of drugs that target the MAPK/ERK signaling pathway, which is often hijacked by cancer cells to promote uncontrolled growth. 

  • Pan-Mutant Inhibition: Unlike first-generation BRAF inhibitors, claturafenib inhibits multiple classes of BRAF mutations, including Class 1 (V600), Class 2, and Class 3 alterations.
  • Brain-Penetrant: It is designed to cross the blood-brain barrier, allowing it to potentially treat brain metastases or primary brain tumours.
  • Dimer Disruption: It works by disrupting the formation of BRAF-containing dimers, which are responsible for signaling in many resistant or non-V600 mutant cancers.
  • Selectivity: It is highly selective for mutant BRAF, significantly sparing normal (wild-type) cells to reduce off-target side effects. 

🏥 Clinical Status

As of April 2026, claturafenib is in Phase 1 clinical trials. 

  • Target Indications: Advanced solid malignancies, including melanoma, colorectal cancer (CRC), and non-small cell lung cancer (NSCLC).
  • Combination Therapy: It is being studied both as a single agent (monotherapy) and in combination with other drugs like binimetinib (a MEK inhibitor) or cetuximab (an EGFR inhibitor).
  • Ongoing Study: Clinical trial NCT05355701 is currently evaluating its safety, dosage, and efficacy in patients whose disease has progressed on other treatments. 
  • A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.CTID: NCT05355701Phase: Phase 1Status: RecruitingDate: 2026-03-27
  • A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsCTID: NCT05538130Phase: Phase 1Status: RecruitingDate: 2026-03-27

 Claturafenib is an orally bioavailable class 1 and 2 inhibitor of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, claturafenib selectively binds to and inhibits the activity of class 1 and 2 BRAF alterations. This inhibits the proliferation of tumor cells which express these BRAF alterations. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms and fusions of BRAF are associated with a number of neoplastic diseases.

Property Value
Molecular Formula
Molecular Weight490.31 g/mol
CAS Number2754408-94-9
Other NamesARRY-440, PF07799933

📍 Note: Claturafenib is an investigational compound and has not yet been approved by the FDA or other regulatory agencies for general use

SYN

US12303509,

Example 126

SYN

https://patentscope.wipo.int/search/en/detail.jsf?docId=US374019464&_cid=P12-MO553W-18219-1

Example 126

N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide

      A solution of 6-amino-5-chloro-3-methylquinazolin-4(3H)-one (90 mg, 0.42 mmol), tert-butyl (2-chloro-4-fluoro-3-iodophenyl)((3-fluoroazetidin-1-yl)sulfonyl)carbamate (218 mg, 0.429 mmol), tris(dibenzylideneacetone)dipalladium (39 mg, 0.042 mmol), Xantphos (62 mg, 0.10 mmol), and cesium carbonate (279 mg, 0.858 mmol) in toluene (2860 μL) was sparged with argon and heated to 110° C. overnight in a sealed vial. The solution was filtered through Celite®, concentrated, and the residue was stirred in 1 mL of DCM and 1 mL of TFA for 1 hour. The solution was concentrated and purified by reverse-phase chromatography (5-95% MeCN/water, 0.1% TFA) and the product was partitioned between DCM and saturated NaHCO 3. The organic layer was washed with brine, dried over Na 2SO 4, filtered, and concentrated to give N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide (78 mg, 37% yield). 1H NMR (400 MHz, CDCl 3) δ 7.94 (s, 1H), 7.56-7.52 (m, 1H), 7.51 (d, 1H), 7.19-7.14 (t, 1H), 6.99-6.95 (m, 1H), 6.72 (s, br, 1H), 6.47 (s, br, 1H), 5.35-5.15 (m, 1H), 4.25-4.10 (m, 4H), 3.57 (s, 3H); MS (apci, m/z)=490.1, 492.1 (M+H).

PAT

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE.........Integrated Solutions, Manufacturing Solutions, Products,
Can't Find? Let's Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

str1

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

////////claturafenib, ANAX, B-Raf (BRAF) inhibitor, antineoplastic, PF-07799933, PF 07799933, ARRY440, ARRY 440, PC35M52J8T

#claturafenib, #ANAX, #B-Raf (BRAF) inhibitor, #antineoplastic, #PF-07799933, #PF 07799933, #ARRY440,#ARRY 440, #PC35M52J8T

Posted by at No comments:

Colfosceril miristate

 

Colfosceril miristate

CAS 18194-24-6

MF C36H72NO8P MW677.9325

1,2 Dimyristoyl glycero 3 phosphorylcholine

(2R)-2,3-bis(tetradecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
surfactant replacement, DIMYRISTOYL LECITHIN, Dimyristoyllecithin, DMCP, DMPC

Colfosceril miristate (1,2-dimyristoyl-sn-glycero-3-phosphocholine or DMPC) is a synthetic phospholipid commonly used in research to study lipid bilayers, liposomes, and drug delivery systems. It serves as a model membrane system due to its phase transition properties and has shown potential in enhancing nanoparticle uptake and acting as a drug stabilizer. 

Key Aspects of Colfosceril Miristate (DMPC):

  • Scientific Application: Primarily used in laboratory research for studying lipid monolayers and bilayers.
  • Drug Delivery: Employed in the creation of liposomes for drug delivery applications.
  • Biological Activity: Exhibits antiproliferative effects on various tumor cell lines and can increase the cellular uptake of nanoparticles.
  • Characteristics: It is a synthetic phospholipid, frequently studied for its phase transition temperature (approx. ).
  • Storage: Should be stored at  or  to maintain stability. 

Important Distinction:
It is crucial not to confuse Colfosceril miristate (DMPC) with Colfosceril palmitate (DPPC). Colfosceril palmitate is a different synthetic surfactant historically used in medicine to treat neonatal respiratory distress syndrome

1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE (dimyristoyl phosphatidylcholine, DMPC) is a synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. DMPC is a frequently studied artificial lipid because it undergoes a phase transition at a convenient temperature. Upon cooling below 23.6°C it undergoes a transition from the liquid crystalline phase to the solid rippled phase, characterized by periodic corrugations of the bilayer.

Dimyristoylphosphatidylcholine is a phosphatidylcholine, a kind of phospholipid. Along with other lipids, it can be used to prepare liposomes.[1]

PAT

US5798091

https://patentscope.wipo.int/search/en/detail.jsf?docId=US38880783&_cid=P12-MO6KKB-34327-1

PAT

Compositions of Phosphorylated Tau Peptides and Uses Thereof

Publication Number: US-2025326806-A1

str1

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

Names
Systematic IUPAC name(2R)-2,3-Bis(tetradecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
Other names1,2-dimyristoylphosphatidylcholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-ditetradecanoyl-sn-glycero-3-phosphocholine, DMPC, 14:0 PC
Identifiers
CAS Number18194-24-6
3D model (JSmol)Interactive image
ChEBICHEBI:45240
ChEMBLChEMBL1235508
ChemSpider4573168
ECHA InfoCard100.038.245 
EC Number242-085-9
PubChem CID5459377
UNII52QK2NZ2T0
CompTox Dashboard (EPA)DTXSID00860227 
InChI
SMILES
Properties
Chemical formulaC36H72NO8P
Molar mass677.945 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).Infobox references

References

  1.  Liposomal drug delivery system from laboratory to clinic, N. A. Kshirsagar, S. K. Pandya, G. B. Kirodian, S. Sanath, Journal of Postgraduate Medicine, 51 (#5) (2005), pp. 5-15, PMID 16519249.

//////////colfosceril miristate, ANAX LAB, surfactant replacement, DIMYRISTOYL LECITHIN, Dimyristoyllecithin, DMCP, DMPC

#colfosceril miristate, #ANAX LAB, #surfactant replacement, #DIMYRISTOYL LECITHIN, #Dimyristoyllecithin, #DMCP, #DMPC

Posted by at No comments:
Subscribe to: Posts (Atom)